“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.
"The good news is that women have been entering medicine in increasing numbers for more than three decades. The not-so-good news is that women are still underrepresented and underutilized in positions of power," writes Deborah M. Shlian, MD, MBA.
In this companion article, Armine K. Smith, MD, reflects on the role of kidney-sparing approaches for LG UTUC and emphasizes the importance of patient-provider communication when making treatment decisions.
Ransomware has never been a more serious threat for health care organizations, even small medical practices.
Closing out their discussion on how treatment and management of advanced prostate cancer affects their clinical practice, expert urologists consider how the therapeutic landscape continues to evolve and look toward future evolutions in care.
A nurse practitioner discusses how she supports multiple providers in a large academic practice.
Learning curve for technique is short, but capital expenditures are required.
"We need health systems, state medical boards and physician employment settings to commit to prioritizing physician wellbeing and provide the reassurances and resources that encourage physicians in need to seek help," writes Russell Libby, MD.
"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
The panel offers key takeaways on the evolving landscape for imaging and biopsy in prostate cancer, highlighting the role for fusion-guided biopsy in the diagnosis and management of prostate cancer.
The request comes amid growing concerns about the rule’s implications for businesses and employees nationwide.
A recap of presentations from AUA 2021 highlighting next steps using novel therapies as combination approaches to treat advanced prostate cancer.
"I hope this achievement serves as a positive example for young women...of what we can accomplish together!" says Leslie M. Rickey, MD, MPH.
Dr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence.
“MRI-based screening showed lower proportions of screening-positive cases, lower false positive rates, and higher PPVs [positive predictive values] than those of PSA-based screening,” noted Taek Min Kim, MD.
The Cures Act has teeth and consumers are becoming increasingly aware of their right to obtain their information.
Patient subgroups that favored nivolumab vs placebo included patients with sarcomatoid features (HR, 0.42; 95% CI, 0.17-1.07), PD-L1 expression of 1% or greater (HR, 0.53; 95% CI, 0.22-1.29), and those with lower limit of normal hemoglobin at baseline (HR, 0.49; 95% CI, 0.25-1.49).
“Our data showed a considerable gap in reporting patient-reported outcomes and in the quality of design and conduct of patient-reported outcomes-related trial endpoints," said Jad Chahoud, MD, MPH.
"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.
Some Ascension hospitals continue to divert ambulances to other facilities for emergency treatment, but some of the system’s hospitals are accepting all patients.
The expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.
"As more patients become interested in remote patient monitoring and case studies continue to show improved patient outcomes, practices must seek ways to integrate these tools into their workflows," writes Lucienne Marie Ide, MD, PhD.
Dr Jason Hafron concludes his discussion of mCSPC by highlighting the need to work towards a cure for the disease, and two major clinical trials investigating triplet treatment regimens.
Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
CCM programs can engage multiple providers to care for patients while reducing in-person visits.
Jeremy D. Sherer, JD, explains everything physicians need to know about using telemedicine in their practice in 2023.
"Despite the uncertain times, I am grateful to be a student in the field of medicine, where compassion is one of the traits that defines its practitioners," says PA student Steffanie Robertus.
The panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods.
In the third article of the series, Melanie McGilloway, NP-C, an advanced practice provider at Genesis Urology in San Diego, discusses the various formulations of leuprolide, a gonadotropin-releasing hormone (GnRH) agonist used for treating advanced prostate cancer.